Almac Pod
Craigavon, N.I., UK, October 16, 2017-
Almac Group
, the global contract development and manufacturing organization, has recognized the need for a change in dynamics of temperature controlled shipping with the launch of its new
Almac Pod
™ service solution in the United States. Understanding the cost, logistical, and compliance challenges posed by this changing environment, the Almac Pod was originally released in Europe and serves as a first-to-market service solution. The innovative solution incorporates the efficiencies of the Almac-approved, global courier network and advanced phase change material technology (PCM) to create a temperature-controlled shipping service solution that eases the burden for its global clinical supply customers. The Almac Pod offers a Protected, Optimized and Dynamic solution which safeguards customers’ products and mitigates against temperature excursions of all clinical shipments-the perfect solution for biologics or difficult to handle products. Since launching the service, the Almac Pod has been 100% effective in protecting the integrity of shipped products with no known temperature excursions within the shipper qualification period. Leon Supplee, Director of Logistics, Almac Clinical Services, commented: “On the cusp of our success launching the Almac Pod in Europe, we have expanded our new temperature-controlled shipping service solution to the United States and internationally. Our customers continuously need a solution to keep pace with rapidly growing demand for controlled temperature shipments. With increased volume, the Almac Pod allows us to build on our streamlined clinical trial supply chain. The service has equipped us, and our clients, to work seamlessly across the logistics process by protecting temperature controlled products and compares more effectively than traditional water-based solutions. The Almac Pod is fully GDP-compliant and is available as part of Almac’s end-to-end, global supply chain management solution-your product, safe in our hands.” For further details on the Almac Pod, download the whitepaper: Changing the Dynamics of Temperature Controlled ShippingSolutions
here
. About Almac Group ‘Partnering to Advance Human Health’ The Almac Group is a contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. The international company is a privately owned organization that has organically grown over almost 50 years and now employs in excess of 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California), and in Asia (Singapore and Tokyo). To keep up to date with our latest releases, follow us on
and
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.